0512-67998889(Suzhou)
18051093220(Shenzhen)
At the signing ceremony, the two parties reached a strategic cooperation on the IND application of the clinical pipeline RR-M01. RocRock Biotech's founder, Yin Xiushan, and Boteng Biopharma's CEO, Tao Rong, attended the signing ceremony. On March 19, 2024, RocRock Biotech Co., Ltd. (hereinafter referred to as "RocRock Biotech") and Suzhou Boteng Biopharma Co., Ltd. (hereinafter referred to as "Boteng Biopharma") held a strategic cooperation ceremony in Suzhou. RocRock Biotech has been focusing on the research of macrophage drug therapy for cancer for many years. In 2023, RocRock Biotech, in collaboration with the Affiliated Hospital of Xuzhou Medical University, initiated an Investigator Initiated Trial (IIT) of the RR-M01 pipeline and successfully completed the dosing assessment of the first subject. The conduct of this clinical trial indicates that the RR-M01 pipeline has good drug safety and potential efficacy, bringing new hope for the treatment of malignant solid tumors, especially recurrent and refractory ovarian cancer. Currently, the indications for the RR-M01 pipeline have been further expanded to all solid tumors that are HER2-positive or have low expression, and in early March 2024, it obtained ethical approval from the Affiliated Hospital of Xuzhou Medical University, with plans to recruit 20 patients in 2024. Boteng Biopharma, as a professional gene and cell therapy CDMO, has established CRO and CDMO platforms including plasmids, viral vectors, cell therapy, gene therapy, and nucleic acid therapy, and has accumulated rich project experience. Through this strategic cooperation, RocRock Biotech will leverage Boteng Biopharma's mature experience and related resources to advance the IND application of the RR-M01 pipeline. This collaboration is a selfless, family-oriented, and nation-oriented initiative, bringing new hope for the treatment of malignant solid tumors, especially recurrent and refractory solid tumors.
(Negotiation and signing)
RocRock Biotech CEO Yin Xiushan said:
"We are very pleased to reach a strategic cooperation with Boteng Biopharma, a very mature CDMO company, especially in the field of cell therapy, where they have accumulated
rich project experience. We believe that Boteng Biopharma's excellent technical team can help RocRock Biotech to rapidly and efficiently advance the research and development of
the new drug RR-M01, and accelerate the clinical registration and market launch process of cell therapy drugs."
Boteng Biopharma CEO and co-founder of Boteng Pharmaceuticals Tao Rong said:
"I am very pleased that we can reach a deep strategic cooperation with RocRock Biotech, an outstanding macrophage drug research and development company. Last year, RocRock
Biotech independently developed the third-generation CAR-M drug RR-M01 injection, which completed the world's first clinical subject dosing and evaluation, and achieved
good results. Accelerating the clinical trial registration of this pipeline to benefit cancer patients as soon as possible is our common goal. We are very grateful for RocRock
Biotech's trust, and Boteng Biopharma will also rely on international technical standards, rigorous experimental design, standardized quality management, and rich project
experience to escort the research and development of new drugs for RocRock Biotech. We hope that with the joint efforts of both parties, we can speed up the development
process of RocRock Biotech's CAR-M drugs, and let good drugs benefit the public sooner."
(Photo of participants)
**About RocRock Biotech:**
RocRock Biotech is a clinical-stage company focused on the research and development of macrophage therapies for cancer and chronic diseases. Incubated in Berlin, Germany,
it was founded by Professor Yin Xiushan, a Chinese scientist returned from Europe, based on over two decades of cutting-edge scientific research. As a strategic high-tech
enterprise in biomedicine, RocRock Biotech is driven by gene editing, cell programming, and targeted delivery technologies. It has completed a multi-location layout in Suzhou
and Berlin, Germany, and has pioneered a closed-loop industry chain centered around macrophage cells. The company's vision is to provide effective solutions for cancer and
chronic diseases and to play a global leading role in the field of macrophage therapy.
**About Boteng Biopharma:**
Suzhou Boteng Biopharma Co., Ltd., established in December 2018, is located in Suzhou Industrial Park and is backed by Chongqing Boteng Pharmaceutical Science and
Technology Co., Ltd. (stock code: 300363), a listed company. It has built CRO and CDMO platforms for plasmids, viral vectors, cell therapy, gene therapy, and nucleic acid therapy,
providing end-to-end services from scientific packaging, library construction, process development, analytical method development, cGMP production to dosage filling,
covering different stages of drug development to help clients accelerate the drug research and marketing process.
Boteng Biopharma focuses on gene and cell therapy, building on the successful experience of Boteng Pharmaceuticals. With a core team of world-class professionals, it adheres
to the service principle of "customer first" and follows the brand philosophy of "compliance, professionalism, focus, and open collaboration." It continues the strong IP
protection and project management mechanisms of its parent company, as well as a comprehensive quality management system. It makes full use of the core team's successful
experience in taking gene and cell therapy products from the clinic to market, providing high-quality and efficient services to global customers, and making good drugs
available to the public sooner.
0512-67998889(Suzhou)
18051093220(Shenzhen)
Cathy.Lv@rocrockbio.com(Suzhou)
lliangjing@rocrockbio.com (Shenzhen)